KB-001 is under clinical development by Keystone Bio and currently in Phase I for Atherosclerosis. According to GlobalData, Phase I drugs for Atherosclerosis have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KB-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KB-001 overview
KB-001 is under development for the treatment of Alzheimer's disease, nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), periodontal disease, peri-implantitis, stroke, atherosclerosis, esophageal cancer, non-smokers lung cancer, oral squamous cell cancer, cardiovascular disease, type 2 diabetes, pneumonia. It is administered by oral route.
Keystone Bio overview
Keystone Bio, Inc., is a developer of a suite of antibodies intended to cure Alzheimer’s and Heart Disease. The company is headquartered in St. Louis, Missouri, the US.
For a complete picture of KB-001’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.